AffyXell Therapeutics develops next-generation cell and gene therapies using mesenchymal stem cells (MSCs) enhanced with Affimer® technology to restore immune balance. The company targets autoimmune diseases and transplant rejection by addressing the underlying immune dysregulation through its proprietary AFX platform.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for autoimmune diseases and transplant rejection often fail to address the underlying immune dysregulation, leading to limited efficacy and potential side effects. Traditional mesenchymal stem cell (MSC) therapies have limitations in their ability to precisely modulate the immune system and restore balance.
Solution
AffyXell Therapeutics is developing a new class of cell and gene therapies that enhance MSCs with Affimer® technology to restore immune balance. Their proprietary AFX platform engineers MSCs to express Affimer proteins, which precisely target and modulate key components of the immune system. This approach aims to provide a more targeted and effective treatment for autoimmune diseases and transplant rejection by addressing the root cause of immune dysregulation. The company's technology seeks to overcome the limitations of traditional MSC therapies by creating a next-generation cell and gene therapy with improved immunomodulatory function.
Target Audience
The primary target audience includes patients with autoimmune diseases and individuals undergoing organ transplantation, as well as clinicians and researchers in the fields of immunology and regenerative medicine.
Features
- MSCs enhanced with Affimer® technology for targeted immune modulation
- Proprietary AFX platform for engineering Affimer expression in MSCs
- DW-MSC platform for large-scale manufacturing of allogenic cell therapy
- Targets autoimmune diseases and transplant rejection
- Aims to restore immune balance by addressing underlying immune dysregulation